Recent

% | $
Quotes you view appear here for quick access.

Stellar Biotechnologies, Inc. Message Board

  • robert.vince robert.vince Mar 19, 2013 9:35 AM Flag

    Stellar Biotechnologies Submits Biological Master File to U.S. FDA for Subunit KLH

    PORT HUENEME, CA, (March 19, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today announced the Company has submitted a Type IV Biologics Master File (BB-MF) to the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) for its subunit KLH.

    A Biologics Master File is a confidential, detailed dossier submitted to the FDA which contains the proprietary information on the manufacture and safety of a drug component.

    Stellar continually updates and maintains master files at the FDA for its KLH products. These files allow Stellar to provide controlled access to a single source of information on file with the FDA, for customers to reference as part of their product applications.

    This new BB-MF is intended to support Stellar’s KLH customers who file applications under the CBER division, thus expanding applicability of the Company’s KLH for broader uses.

    Stellar’s goal is to help accelerate the regulatory approval process for products that use the Company’s KLH. Only Stellar KLH is derived from proprietary, cultured keyhole limpet colonies. This allows Stellar to deliver an unprecedented level of control over its KLH quality and performance; benefits valued by vaccine manufacturers and drug developers using KLH.

    “Stellar is always looking for effective ways to support our customers’ applications through the regulatory process,” commented Catherine Brisson, Chief Pharmaceutical Officer at Stellar Biotechnologies. “We are very pleased to have this master file submitted to CBER. By ensuring that the information required by FDA is accessible, we can facilitate regulatory approvals for KLH-based products.”

 
SBOTF
0.890.00(0.00%)Mar 30 3:51 PMEDT